Mochida Pharmaceutical Co.,Ltd. (4534.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	108.9B	117.0B	105.2B	102.9B	103.3B
Cost of Revenue	13.0B	60.7B	51.4B	50.8B	48.1B
Gross Profit	13.6B	56.3B	53.8B	52.1B	55.1B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	11.1B	46.1B	45.7B	46.3B	46.6B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	11.1B	46.1B	45.7B	46.3B	46.6B
Cost and Expenses	100.4B	106.8B	97.0B	97.1B	94.8B
Operating Income (EBIT)	8.5B	10.1B	8.1B	5.8B	8.5B
Non-Operating
Interest Income	15.0M	112.0M	29.0M	2.0M	2.0M
Interest Expense	—	72.0M	3.0M	2.0M	—
Net Interest Income	15.0M	40.0M	26.0M	—	2.0M
Other Non-Op Income/Expense	210.0M	1.0B	(58.0M)	235.0M	578.0M
Non-Operating Income (excl Interest)	270.0M	1.4B	562.0M	508.0M	663.0M
EBT (Pre-Tax Income)	2.8B	11.2B	8.1B	6.2B	9.0B
Income Tax Expense	888.0M	3.3B	2.4B	1.6B	2.4B
Bottom Line
Net Income	5.5B	7.9B	5.7B	4.5B	6.6B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	5.5B	7.9B	5.7B	4.5B	6.6B
Per Share
Basic EPS	¥155	¥223	¥160	¥127	¥179
Diluted EPS	¥155	¥223	—	—	—
Revenue Per Share	¥3,071	¥3,299	¥2,966	¥2,869	¥2,779
Shares
Basic Shares Outstanding	35.5M	35.5M	35.5M	35.9M	37.2M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	13.1B	11.1B	8.6B	11.2B
D&A	—	3.0B	2.9B	2.8B	2.7B
EBIT	8.5B	10.1B	8.1B	5.8B	8.5B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026